{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "epsTrailingTwelveMonths": -0.88, "epsForward": 0.74, "epsCurrentYear": -0.23, "priceEpsCurrentYear": -10.695652, "sharesOutstanding": 44583700, "bookValue": 0.608, "fiftyDayAverage": 2.23882, "fiftyDayAverageChange": 0.22117996, "fiftyDayAverageChangePercent": 0.0987931, "twoHundredDayAverage": 2.895375, "twoHundredDayAverageChange": -0.43537498, "twoHundredDayAverageChangePercent": -0.15036911, "marketCap": 110918944, "forwardPE": 3.3243244, "priceToBook": 4.046053, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "2.0 - Buy", "tradeable": false, "cryptoTradeable": false, "currency": "EUR", "financialCurrency": "USD", "regularMarketOpen": 2.46, "averageDailyVolume3Month": 97, "averageDailyVolume10Day": 92, "fiftyTwoWeekLowChange": 0.61, "fiftyTwoWeekLowChangePercent": 0.32972974, "fiftyTwoWeekRange": "1.85 - 5.018", "fiftyTwoWeekHighChange": -2.558, "fiftyTwoWeekHighChangePercent": -0.50976485, "fiftyTwoWeekLow": 1.85, "fiftyTwoWeekHigh": 5.018, "earningsTimestamp": 1676469601, "earningsTimestampStart": 1684153800, "earningsTimestampEnd": 1684499400, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "firstTradeDateMilliseconds": 952585200000, "priceHint": 4, "marketState": "REGULAR", "regularMarketChange": -0.01999998, "regularMarketTime": 1683871252, "regularMarketDayHigh": 2.46, "regularMarketDayRange": "2.46 - 2.46", "regularMarketDayLow": 2.46, "regularMarketVolume": 275, "regularMarketPreviousClose": 2.48, "bid": 2.32, "ask": 2.34, "bidSize": 0, "askSize": 0, "fullExchangeName": "Frankfurt", "regularMarketChangePercent": -0.80645084, "regularMarketPrice": 2.46, "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "esgPopulated": false, "exchange": "FRA", "shortName": "CEL-SCI CORP. NEW  DL-,01", "longName": "CEL-SCI Corporation", "messageBoardId": "finmb_258746", "market": "dr_market", "symbol": "LSRM.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "8229 Boone Boulevard", "address2": "Suite 802", "city": "Vienna", "state": "VA", "zip": "22182", "country": "United States", "phone": "703 506 9460", "website": "https://cel-sci.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research, development, and manufacturing of immune systems for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, a Leukocyte Interleukin injection, which has completed a pivotal Phase 3 clinical trial for patients, who are diagnosed with locally advanced primary squamous cell carcinoma of the head and neck. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company is developing CEL-2000 and CEL-4000 which are LEAPS based product candidates for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Geert R. Kersten Esq.", "age": 63, "title": "Chief Exec. & Financial Officer, Treasurer and Director", "yearBorn": 1959, "fiscalYear": 2022, "totalPay": {"raw": 681986, "fmt": "681.99k", "longFmt": "681,986"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 503077, "fmt": "503.08k", "longFmt": "503,077"}}, {"maxAge": 1, "name": "Ms. Patricia B. Prichep", "age": 71, "title": "Sr. VP of Operations & Corp. Sec.", "yearBorn": 1951, "fiscalYear": 2022, "totalPay": {"raw": 286030, "fmt": "286.03k", "longFmt": "286,030"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 251668, "fmt": "251.67k", "longFmt": "251,668"}}, {"maxAge": 1, "name": "Dr. Eyal  Talor Ph.D.", "age": 66, "title": "Chief Scientific Officer", "yearBorn": 1956, "fiscalYear": 2022, "totalPay": {"raw": 340588, "fmt": "340.59k", "longFmt": "340,588"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 233318, "fmt": "233.32k", "longFmt": "233,318"}}, {"maxAge": 1, "name": "Dr. Daniel H. Zimmerman Ph.D.", "age": 81, "title": "Sr. VP of Research & Cellular Immunology", "yearBorn": 1941, "fiscalYear": 2022, "totalPay": {"raw": 262856, "fmt": "262.86k", "longFmt": "262,856"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 118084, "fmt": "118.08k", "longFmt": "118,084"}}, {"maxAge": 1, "name": "Mr. John  Cipriano", "age": 80, "title": "Sr. VP of Regulatory Affairs", "yearBorn": 1942, "fiscalYear": 2022, "totalPay": {"raw": 239105, "fmt": "239.1k", "longFmt": "239,105"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 176842, "fmt": "176.84k", "longFmt": "176,842"}}], "auditRisk": 10, "boardRisk": 10, "compensationRisk": 10, "shareHolderRightsRisk": 6, "overallRisk": 10, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}